Dr. Reddy’s vs Aurobindo Pharma: share price, P/E, ROE and financials compared
Dr. Reddy's Laboratories
Aurobindo Pharma
Dr. Reddy’s and Aurobindo Pharma at a glance
Dr. Reddy’s and Aurobindo Pharma are both listed in Healthcare. Dr. Reddy’s is the larger by market cap, at ₹1.1L Cr against ₹1.0L Cr for Aurobindo Pharma. On valuation, Aurobindo Pharma has the lower P/E (26.1× against 40.9×) and the lower price-to-book (2.63× against 2.96×). On returns and margins, Dr. Reddy’s has the higher ROCE (14.2% against 13.5%), while Aurobindo Pharma has the higher ROE (10.7% against 7.3%) and the higher operating margin (20.6% against 15.9%). Over three years, Aurobindo Pharma has faster 3-year profit growth (+22.0% against −1.7% a year). Debt-to-equity is similar, 0.19× for Dr. Reddy’s and 0.22× for Aurobindo Pharma.
Key metrics, side by side
| Metric | Dr. Reddy’sDRREDDY | Aurobindo PharmaAUROPHARMA |
|---|---|---|
| Price (₹) | 1,373.00 | 1,800.00 |
| Market cap (₹ Cr) | 1,14,462 | 1,03,568 |
| P/E | 40.9× | 26.1× (the lower figure, shaded) |
| P/B | 2.96× | 2.63× (the lower figure, shaded) |
| Dividend yield, trailing | 0.58% (the higher figure, shaded) | 0.00% |
| ROE | 7.3% | 10.7% (the higher figure, shaded) |
| ROCE | 14.2% (the higher figure, shaded) | 13.5% |
| Operating margin (OPM) | 15.9% | 20.6% (the higher figure, shaded) |
| Net margin (NPM) | 8.5% | 10.8% (the higher figure, shaded) |
| Sales CAGR 3Y | +11.0% | +10.7% |
| Profit CAGR 3Y | −1.7% | +22.0% (the higher figure, shaded) |
| Debt to equity | 0.19× | 0.22× |
| Interest cover | 15.7× | 15.5× |
| Net profit TTM (₹ Cr) | 2,799 | – |
| 1Y return | +13.8% | +55.3% (the higher figure, shaded) |
| Promoter holding | 26.63% | 51.88% |
Dr. Reddy’s vs Aurobindo Pharma: common questions
Which is bigger, Dr. Reddy’s or Aurobindo Pharma?
By market cap, Dr. Reddy’s is bigger at ₹1.1L Cr, against ₹1.0L Cr for Aurobindo Pharma (prices as of 6 Nov 2026).
Which has a lower P/E ratio, Dr. Reddy’s or Aurobindo Pharma?
Dr. Reddy’s trades at a P/E of 40.9× and Aurobindo Pharma at 26.1×. Aurobindo Pharma has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Dr. Reddy’s or Aurobindo Pharma?
Dr. Reddy’s reports a return on equity of 7.3% and Aurobindo Pharma 10.7%. Aurobindo Pharma has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Dr. Reddy’s or Aurobindo Pharma?
Over the last three years: Sales grew +11.0% a year at Dr. Reddy’s and +10.7% at Aurobindo Pharma; profit grew −1.7% a year at Dr. Reddy’s and +22.0% at Aurobindo Pharma, so Aurobindo Pharma grew profit faster. Past growth doesn’t predict future growth.